DNAVEC starts production of iPS cells based on a Sendai virus vector

The production is directed towards clinical application and based on the use of a Sendai virus “GMP-CytoTune-iPS” under GMP standards.

DNAVEC website news, Nov. 13, 2014

Most popular posts: